Madrigal Pharmaceuticals Inc

Research Madrigal Pharmaceuticals Inc (MDGL) on Bullrun: market cap USD 12.16B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMDGL
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 12.16B
• Financial periodFY2025
• RevenueUSD 958.40M
• Revenue growth432.1%
• Net income-USD 288.28M
• Free cash flow-USD 190.02M

Valuation Snapshot

latest market cap is USD 12.16B.

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Frequently asked questions

What is Madrigal Pharmaceuticals Inc's market cap?

Madrigal Pharmaceuticals Inc's market capitalization is USD 12.16B.

What does Madrigal Pharmaceuticals Inc do?

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.